Sun.May 05, 2024

article thumbnail

Results show potential of J&J’s TAR-210 to transform treatment of bladder cancer with FGFR alterations

Express Pharma

Phase 1 trial shows 90 per cent recurrence-free survival and 90 per cent complete response in patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer, respectively Janssen-Cilag International NV, a Johnson & Johnson company, recently updated results from an open-label, multicentre, multi-cohort Phase 1 study of the safety and efficacy of TAR-210, an intravesical targeted releasing system designed to provide sustained, local release of erdafitinib into the bladder, i

article thumbnail

New patent expiration for Wyeth Pharms drug DUAVEE

Drug Patent Watch

Annual Drug Patent Expirations for DUAVEE Duavee is a drug marketed by Wyeth Pharms and is included in one NDA. It is available from two suppliers.

59
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Episode 919: The problem with hypo-osmolar solutions in neurological patients

Pharmacy Joe

In this episode, I’ll discuss the problem with hypo-osmolar solutions in neurological patients. Episode 919: The problem with hypo-osmolar solutions in neurological patients Subscribe on iTunes , Android , or Stitcher The administration of hypo-osmolar IV solutions causes an increase in water into the brain. This is because an intact blood-brain barrier is permeable to water but not electrolytes.

article thumbnail

Alembic Pharmaceuticals receives an EIR for its oncology formulation facility

Express Pharma

According to the company’s statement, all EIRs are in place for their USFDA facilities After an inspection carried out by the US Food and Drug Administration ( USFDA), Alembic Pharmaceuticals has received its Establishment Inspection Report (EIR) for its oncology (injectable and oral solid) formulation facility. Located at Panelav, the inspection was carried out from February 28 to March 8, 2024.

52
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

The 7 Habits of Highly Effective People

RX Note

Introduction The 7 Habits of Highly Effective People , first published in 1989, is a business and self-help book by Stephen R. Covey. A sequel, titled The 8th Habit: From Effectiveness to Greatness , followed in 2004. Deep Roots for Lasting Solutions Significant problems we face cannot be solved with the same level of thinking that created them. In all of life, there are sequential stages of growth and development.

52
article thumbnail

SSRIs In Lactation

Med Ed 101

Is it safe for women to breastfeed while taking antidepressants? According to a CDC report from 2020, ~10.3% of women ages 18-39 take antidepressants, and the number of people diagnosed with depression and taking antidepressants continues to rise. In this article, we will look at the use of SSRIs in lactation. All antidepressants pass into […] The post SSRIs In Lactation appeared first on Med Ed 101.

52

More Trending

article thumbnail

Environmental and Social Conditions May Help Predict Severity of Asthma in Children

Pharmacy Times

With these findings contributing to the understanding of neighborhood-level asthma risks, the authors note next steps can involve identifying and addressing disparities.

59
article thumbnail

What's New and What to Do: Critical Updates to Regulatory Requirements for Injectable Packaging

PharmaTech

Webinar Date/Time: Tue, Jun 4, 2024 9:00 AM EDT

article thumbnail

DEA Concurs: Marijuana Meets Schedule III Criteria

FDA Law Blog: Biosimilars

By Larry K. Houck — The Associated Press reported on Tuesday following confirmation by five anonymous individuals with knowledge that the Drug Enforcement Administration (“DEA”) is moving to reschedule marijuana from schedule I to the less stringently controlled schedule III. US poised to ease restrictions on marijuana in historic shift, but it’ll remain controlled substance (Apr. 30, 2024).